Friday, April 25 - Saturday, April 26, 2025
Hyatt Regency Lake Tahoe Resort, Incline Village, Nevada
Please contact Johanna Bell for questions at bellj@med.unr.edu.
Sponsored by: William N. Pennington Cancer Institute
3rd Annual Pennington Cancer Institute Cancer Conference
Overview
Cancer screening, early detection, and treatment are rapidly changing, with new technologies and therapies being introduced. This year almost 2 million Americans will be diagnosed with cancer. Therefore, it is critical for primary care providers to remain current with guidelines. Understanding the initial cancer therapy is also essential for optimal patient care, as patients often seek information from multiple sources, including their primary providers. This conference will address numerous topics related to common forms of cancer commonly seen and often diagnosed by PCPs.
Who Should Attend
Physicians, Advanced Practice Nurses, Nurses, PAs, Medical Researchers, and Pharmacists
Registration
This is an in-person CME event
Includes welcome reception, Saturday continental breakfast and lunch, and CME/CE credit. The early registration deadline is April 2, 2025. After April 2, 2025, registration increases.
Early registration (on or before April 2, 2025)
Friday only: $50
Saturday: $100
Both days: $125
Late registration (April 3 - 16, 2025)
Friday only: $70
Saturday: $125
Both days: $150
Registration closes April 18. After April 18, please contact Johanna Bell at bellj@med.unr.edu to inquire if late registration opportunities are available.
Discounted registration is available for UNR Med Faculty, Medical Students and Residents. For additional information, please call (775) 784-1451 or bellj@med.unr.edu.
Cancellation Policy
Cancellations received by March 28, 2025 will receive a full refund less a $25 cancellation fee. Cancellations after March 28, 2025 are non-refundable.
Program Support
This program is supported by William N. Pennington Cancer Institute.
The contents are those of the author(s) and do not necessarily represent the official views of Renown Health.
| Time | Event |
|---|---|
| 12:30 - 12:40 p.m. | Welcome and Introduction Lee Schwartzberg, M.D., FACP, Medical Oncology, William N Pennington Cancer Institute |
| 12:40 - 1:10 p.m. | State of Cancer Care in 2025 Lee Schwartzberg, M.D., FACP, Medical Oncology, William N Pennington Cancer Institute |
| 1:10 - 1:50 p.m. | Advances in Breast Cancer William Gradishar, M.D., Professor of Breast Oncology Northwestern Medicine, Northwestern University, Feinberg School of Medicine |
| 1:50 - 2:30 p.m. | Advances in Multiple Myeloma Rafael Fonseca, M.D., Hematologist, Bone Marrow Transplant Program, Mayo Clinic Comprehensive Cancer Center |
| 2:30 - 3:10 p.m. | Advances in Non-Small Cell Lung Cancer Edward Garon M.D., Director, Thoracic Oncology Program Jonsson Comprehensive Cancer Center at University of California, Los Angeles |
| 3:10 - 3:40 p.m. | Break and Exhibits |
| 3:40 - 4:20 p.m. | Advances in Colorectal Cancer Cathy Eng, M.D., FACP, FASCO, Chair in Surgical and Medical Oncology, Professor of Medicine, Vanderbilt-Ingram Cancer Center |
| 4:20 - 5:00 p.m. | Advances in Leukemia George Yaghmour, M.D., Associate Director Blood and Bone Marrow Transplant Program, USC Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California |
| 5:00 - 5:10 p.m. | Closing Remarks Lee Schwartzberg, M.D., FACP, Medical Oncology, William N Pennington Cancer Institute |
| 5:10 - 6:30 p.m. | Welcome Reception and Poster Session in Exhibit Space |
| Time | Event |
|---|---|
| 6:30 - 7:30 a.m. | Morning Rise Bootcamp Mena Spodobalski, Certified Personal Trainer, Evoke Fitness |
| 8:00 - 8:45 a.m. | Breakfast and Product Theater (non-CME) in Exhibit Space |
| 8:45 - 9:15 a.m. | Welcome & Pennington Cancer Institute Update Max Coppes, M.D., Ph.D., MBA, Director, William N Pennington Cancer Institute |
| 9:15 - 9:45 a.m. | Genomic Expression Profiling in Breast Cancer Lee Schwartzberg, M.D., FACP, Medical Oncology, William N Pennington Cancer Institute |
| 9:45 - 10:15 a.m. | How Breast Imaging is Used for Surgical Decision Making Michelle Chu, M.D., FACS, Renown Breast Surgery Care, William N Pennington Cancer Institute |
| 10:15 - 10:30 a.m. | Break and Exhibits |
| 10:30 - 12:00 p.m. | Panel Discussion: From Fatigue to Fierce: Supporting Wellness After a Cancer Diagnosis Madeline Hardacre, M.D., Oncology Wellness & Lifestyle Medicine, Monique Germain, D.O., Medical Oncology Abby Baker, P.T., DPT, CLT Certified Oncology Rehabilitation Specialist Jessica Blauenstein, M.S., RDN, LDN, CSO Board Certified Specialist in Oncology Nutrition |
| 12:00 - 1:00 p.m. | Lunch and Product Theater (Non-CME) |
| 1:00 - 1:45 p.m. | High Risk Genetics of Breast Cancer & GI Genetics Risks Christina Alsop, DNP, APRN, FNP-BC, AOCNP, Medical Oncology, William N Pennington Cancer Institute Harry Menon, D.O., Medical Oncology, William N Pennington Cancer Institute Michelle Hearn, MS, LCGC, Genome Medical |
| 1:45 - 2:15 p.m. | Updates in Lung Cancer Screening & Early Stage Lung Cancer Detection Katie Graham, D.O., MPH, FAAFP, Family Medicine, Pulmonology Medicine, Renown Health |
| 2:15 - 3:00 p.m. | Management and Follow Up of Early Stage Lung Cancer Luis Alberton, M.D., FACS, Thoracic Surgeon, Logan Health |
| 3:00 - 3:20 p.m. | Break and Exhibits |
| 3:20 - 3:50 p.m. | Management and Cancer Surveillance of the Cirrhotic Patient Alicia Gingrich, M.D., M.S., Surgical Oncology, William N. Pennington Cancer Institute |
| 3:50 - 4:20 p.m. | Liver Directed Therapies and New Technologies Nick Manguso, M.D., Surgical Oncology, William N. Pennington Cancer Institute |
| 4:20 - 4:30 p.m. | Closing Remarks Kate Ward, PharmD, BCPS, Vice President of Oncology, William N. Pennington Cancer Institute |
Learning Objectives
Following participation in this course, participants should be able to:
- Identify current state of multidisciplinary care in Oncology
- Evaluate workforce issues and regulatory issues on the current/future direction of AI solutions
- Review new practice-changing data for all breast cancer subtypes that have emerged within the last year.
- Discuss and examine controversial management issues in hormone receptor-positive early breast cancer patients
- Describe the current management of advanced non-small cell lung cancer (NSCLC)
- Define the targeted therapies for NSCLC
- Report the controversies with eligibility criteria
- Assess the value of Next-generation testing and its significance for selecting therapy in the management of patients with metastatic colorectal cancer (mCRC)
- Evaluate efficacy data from practice-changing clinical trials on new and emerging molecularly-directed therapies for patients mCRC
- Outline the current standard of care for bone and soft tissue sarcoma and explain emerging treatments in sarcoma
- Review current management strategies of osseous metastatic disease in the appendicular skeleton and pelvis
- Outline and discuss current services and future goals of the Pennington Cancer Institute
- Review and discuss Lung Cancer Screening and advances in Bronchoscopy and diagnosis
- Contrast differences between population screening and diagnostic genetic testing
- Distinguish between monogenic and polygenic breast cancer risk
- Outline quantitative risk categories of low, normal, and high risks for breast cancer
- Recognize the implications of PSA screening policies on the population and the basis for when to start and stop PSA screening
- Demonstrate the process of Lung, GI, and Breast Cancer tumor boards as panels of cancer experts conduct discussions of real patients to reach a multidisciplinary treatment plan consensus
- Explain the neurobiological challenges for advancing treatment of brain tumors
- Describe the principle mechanism of laser interstitial thermal therapy and its role in treating brain tumors and radiation necrosis
- Describe the role of palliative care in an oncology practice and examine the experience oncology patients will have in a palliative care visit.
Hyatt Regency Lake Tahoe Resort
111 County Club Drive
Incline Village, Nevada 89451
Directions
Discounted guest room rates are available for conference attendees on Friday, April 25th, and Saturday, Apri 26th. Room rates do not include local and state taxes. All rooms are subject to a resort fee of $40 per room, per night.
Single or Double Occupancy: $229 (plus applicable taxes and resort fee)
Triple Occupancy: $254 (plus applicable taxes and resort fee)
Quadruple Occupancy: $279 (plus applicable taxes and resort fee)
Rooms are subject to availability, and the reservation deadline is March 28, 2025 to receive the discounted rates.
Guests may make reservations online or by calling (775) 832-1234. Mention the Renown Cancer Institute Conference to receive the discounted group rate.
Renown Cancer Center Institute Conference Online Hotel Reservation Booking
Hotel Parking
On-site self-parking is $20 per car, per night for conference attendees for April 25-26, 2025.
Exhibit opportunities are available. Please see the exhibit prospectus for additional information.
Platinum: $15,000
- Three 6’ draped display tables
- Complimentary registration for up to 6
- First choice of table placement
- Admittance to the Friday evening welcome reception
- Sponsorship of Lunch Non-CME lecture
- Recognition as a Platinum sponsor on website, and welcome PowerPoint –Name only, no logos
- Sponsor level ribbon – Platinum
- Verbal thank you from the podium during welcome remarks
- Two breaks and lunch break during the meeting for attendees to network
Gold: $7,500
- Two 6’ draped display table
- Complimentary registration for up to 4
- Admittance to the educational sessions
- Admittance to the Friday evening welcome reception
- Recognition as a Gold sponsor on website, and welcome PowerPoint – Name only, no logos
- Sponsor level ribbon – Gold
- Verbal thank you from the podium during welcome remarks
- Two breaks and lunch break during the meeting for attendees to network
Silver: $5,000
- One 6’ draped display table
- Complimentary registration for 2
- Admission to the educational sessions
- Admittance to the Friday evening welcome reception
- Recognition as a Silver sponsor on website, and welcome PowerPoint – Name only, no logos
- Sponsor level ribbon – Silver
- Verbal thank you from the podium during welcome remarks
- Two breaks and lunch break during the meeting for attendees to network
Standard Exhibitor: $2,500
- One 6’ draped display table
- Complimentary registration for 1
- Two breaks and lunch break during the meeting for attendees to network
Please take a moment to complete the Exhibitor Registration Form. For additional information, please contact Johanna Bell bellj@med.unr.edu or call 775-784-1983.
As an accredited provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME) the University of Nevada, Reno School of Medicine must ensure balance, independence, objectivity, and scientific rigor in all its educational activities. In order to assure that information is presented in a scientific and objective manner, The University of Nevada, Reno School of Medicine requires that anyone in a position to control or influence the content of an accredited activity disclose all financial relationships within the prior 24 months with any commercial or proprietary entity producing health care goods or services relevant to the content being planned or presented. All relevant financial relationships have been mitigated. Following are those disclosures.
The following presenter has disclosed the following relationship with a commercial interest:
Luis Alberton:
- Consultant: Intuitive Surgical
- Ownership Interest (publicly held): J&J, Medtronic, Lilly, Intuitive, Microsoft
Edward Garon:
- Consultant: Abbvie; Arcus; AstraZeneca; Arrivent; Atreca; Black Diamond Therapeutics; BridgeBio; Bristol Myers Squibb; Daiichi-Sankyo; GSK; Eli Lilly; Gilead; Hookipa; I-Mab; iTeos; LianBio; Merck; Merus; Novartis; Nuvalent; Pfizer; Regeneron; Sanofi; Seagan; Sumitomo; Strata; Summit; Synthekine;
- Grant/Research Support: ABL-Bio; Arrivent; AstraZeneca; BridgeBio; Bristol Myers Squibb; Daiichi Sanko; Eli Lilly; EMD Serono; Genentech; Gilead; Iovance Biotherapeutics; Merck; Mirati; Novartis; Prelude; Regeneron; Synthekine; TILT Biotherapeutics
- Other Financial Benefit: Sponsored Independent Medical Education: Daiichi-Sankyo; Travel: A2 Bio, Merck, Regeneron
Michelle Hearn:
- Ownership Interest (privately held):: Genome Medical, INC.
Harry Menon:
- Advisory Board : Genentech, Deciphera, Astrazeneca
- Speakers' Bureau or Honoraria : Astrazeneca, Genentech, Sanofi
All other presenters, planners or anyone in a position to control the content of this continuing medical education activity have indicated that neither they nor their spouse/legally recognized domestic partner has any financial relationships with commercial interests related to the content of this activity.
CME Accreditation and Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nevada, Reno School of Medicine and Renown Health. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education to physicians.
Continuing Medical Education Credit
The University of Nevada, Reno School of Medicine designates this live activity for a maximum of 10.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Nevada, Reno School of Medicine approves this program for 10.00 hours of nursing continuing education credit. Nevada State Board of Nursing provider number 120894-1.